The HR for HF was 0.805 (95% CI 0.784, 0.827; χ2=0.094), for hospitalisation was 0.711 (95% CI 0.703, 0.719; χ2=257.258) and for all-cause mortality was 0.543 (95% CI 0.532, 0.555; χ2=31.611), indicating lower risk of these outcomes in individuals on SGLT2i and insulin therapy. This evidence concerns the gene INS and hydrops fetalis.